Royal Bank of Canada
TELO icon

Royal Bank of Canada’s Telomir Pharmaceuticals TELO Stock Holding History

Royal Bank of Canada’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-599
Closed -$1K – 7726
2025
Q3 		$1K Sell
599
-345
-37% -$520 ﹤0.01% 7046
2025
Q2 		$1K Buy
944
+413
+78% +$955 ﹤0.01% 6951
2025
Q1 		$1K Sell
531
-755
-59% -$3.3K ﹤0.01% 6732
2024
Q4 		$5K Buy
1,286
+137
+12% +$646 ﹤0.01% 6556
2024
Q3 		$8K Buy
1,149
+696
+154% +$3.39K ﹤0.01% 6410
2024
Q2 		$2K Buy
+453
New +$2.83K ﹤0.01% 6760

Other funds holding TELO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Royal Bank of Canada's TELO Position: Q4 2025 in Review

Royal Bank of Canada sold out of Telomir Pharmaceuticals (TELO) in Q4 2025, closing a stake of 599 shares — an estimated $1K sold.

Royal Bank of Canada first reported a position in TELO in Q2 2024 and held it in 6 quarters. The position peaked at $8K in Q3 2024. 33 funds tracked by Wall St. Rank hold TELO as of Q4 2025.

  • Royal Bank of Canada reported no remaining Telomir Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Royal Bank of Canada sold 599 Telomir Pharmaceuticals shares in Q4 2025, an estimated $1K.
  • Royal Bank of Canada first reported a position in Telomir Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Royal Bank of Canada's Telomir Pharmaceuticals position peaked at $8K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q4 2025.

Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.